Aclaris Therapeutics Stock Options
| ACRS Stock | USD 1.24 0.01 0.81% |
Aclaris Therapeutics' option chain provides insight into all available option contracts written on Aclaris Therapeutics' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Aclaris Therapeutics' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Aclaris option contract.
In The Money vs. Out of Money Option Contracts on Aclaris Therapeutics
Analyzing Aclaris Therapeutics' in-the-money options over time can help investors to take a profitable long position in Aclaris Therapeutics regardless of its overall volatility. This is especially true when Aclaris Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Aclaris Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Aclaris Therapeutics' stock while costing only a fraction of its price.
Aclaris Therapeutics' latest option contracts expiring on 2024-04-19 are carrying combined implied volatility of 0.0 with a put-to-call open interest ratio of 7.05 over 12 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on 2024-04-19. The current put volume is at 0, with calls trading at the volume of 0. This yields a 0.0 put-to-call volume ratio. The Aclaris Therapeutics option chain provides detailed quote and price information for the current Aclaris Therapeutics option contracts. It shows all of Aclaris Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.
Open Interest Against 2024-04-19 Option Contracts
Aclaris Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Aclaris Therapeutics' lending market. For example, when Aclaris Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Aclaris Therapeutics, he or she must hedge the risk by shorting Aclaris Therapeutics stock over its option's life.
2024-04-19
The chart above shows Aclaris Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Aclaris Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Aclaris Therapeutics' option, there is no secondary market available for investors to trade.
Aclaris Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Aclaris Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Aclaris stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Aclaris Therapeutics' stock price goes up or down, the stock options follow.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. Please note that buying 'in-the-money' options on Aclaris Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Aclaris Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Aclaris Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Aclaris Stock moves the wrong way.
At this time, Aclaris Therapeutics' Common Stock Total Equity is comparatively stable compared to the past year. Common Stock is likely to gain to 1,208 in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 38.5 M in 2024. Aclaris Current Options Market Mood
Aclaris Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Aclaris Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Aclaris Therapeutics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Aclaris Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Aclaris Therapeutics' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current Aclaris contract
Base on the Rule 16, the options market is currently suggesting that Aclaris Therapeutics will have an average daily up or down price movement of about 0.0% per day over the life of the 2024-04-19 option contract. With Aclaris Therapeutics trading at USD 1.24, that is roughly USD 0.0. If you think that the market is fully incorporating Aclaris Therapeutics' daily price movement you should consider buying Aclaris Therapeutics options at the current volatility level of 0.0%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Aclaris |
Purchasing Aclaris Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Aclaris calls. Remember, the seller must deliver Aclaris Therapeutics stock to the call owner when a call is exercised.
Aclaris Therapeutics Option Chain
When Aclaris Therapeutics' strike price is surpassing the current stock price, the option contract against Aclaris Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Aclaris Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Aclaris. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Aclaris. It also shows strike prices and maturity days for a Aclaris Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Call | 2024-04-19 CALL at $0.5 | 0.9547 | 0.1172 | 0 | 2024-04-19 | 0.4 - 1.1 | 0.0 | In |
Call | 2024-04-19 CALL at $1.0 | 0.7477 | 0.5282 | 79 | 2024-04-19 | 0.15 - 0.55 | 0.25 | In |
Put | 2024-04-19 PUT at $1.5 | -0.7844 | 1.077 | 1660 | 2024-04-19 | 0.2 - 0.4 | 0.25 | In |
Put | 2024-04-19 PUT at $2.0 | -0.741 | 0.4942 | 0 | 2024-04-19 | 0.55 - 1.15 | 0.0 | In |
Aclaris Therapeutics Total Stockholder Equity Over Time
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Total Stockholder Equity |
| Timeline |
Aclaris Therapeutics Common Stock Shares Outstanding Over Time
The total number of shares of a company's common stock that are currently owned by all its shareholders. Common Stock Shares Outstanding |
| Timeline |
Aclaris Total Stockholder Equity
Total Stockholder Equity |
|
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aclaris Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Aclaris Therapeutics Corporate Directors
Aclaris Therapeutics corporate directors refer to members of an Aclaris Therapeutics board of directors. The board of directors generally takes responsibility for the Aclaris Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Aclaris Therapeutics' board members must vote for the resolution. The Aclaris Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Humphries | Director | Profile | |
| Andrew Powell | Independent Director | Profile | |
| Richard Bierly | Director | Profile | |
| Ketan Patel | Director | Profile |
Already Invested in Aclaris Therapeutics?
The danger of trading Aclaris Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclaris Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclaris Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclaris Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aclaris Therapeutics is a strong investment it is important to analyze Aclaris Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aclaris Therapeutics' future performance. For an informed investment choice regarding Aclaris Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.